临床数据
CLDA

股本结构

单位：万股
公告日期 2011-02-09 2011-02-09 2010-11-09 2010-11-09 2010-08-09 2010-08-09
证券总股本 3095.49 2995.90 2995.52 2993.30 2985.42 2984.30
普通股本 3095.49 2995.90 2995.52 2993.30 2985.42 2984.30
优先股 未披露 未披露 未披露 未披露 未披露 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2011-02-08 2010-12-31 2010-11-05 2010-09-30 2010-08-06 2010-06-30
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2011-02-09 3095.49 未披露 定期报告 2011-02-08
2011-02-09 2995.90 未披露 定期报告 2010-12-31
2010-11-09 2995.52 未披露 定期报告 2010-11-05
2010-11-09 2993.30 未披露 定期报告 2010-09-30
2010-08-09 2985.42 未披露 定期报告 2010-08-06
2010-08-09 2984.30 未披露 定期报告 2010-06-30
2010-06-14 2968.24 未披露 定期报告 2010-06-14
2010-06-14 2651.90 未披露
更多>>
Equity issued in connection with the Avalon acquisition Public offering, net of transaction costs of $3,262 Exercise of stock options, net of shares surrendered Exercise of stock warrants Stock-based compensation
2010-03-31
2010-02-09 2651.36 未披露 定期报告 2010-02-05
2010-02-09 2650.60 未披露 定期报告 2009-12-31
2009-06-15 2370.24 未披露 定期报告 2009-06-12
2009-06-15 2274.20 未披露
更多>>
from March 31, 2008 to March 31, 2009 Exercise of stock options Exercise of stock warrants Issuance of common stock and warrants, net of transaction costs of $36 Retirement of treasury stock Stock-based compensation
2009-03-31
2008-06-16 2113.99 未披露 定期报告 2008-06-13
2008-06-16 2113.60 未披露
更多>>
from March 31, 2007 to March 31, 2008 Conversion of Series A preferred stock into common stock Exercise of stock options Exercise of stock warrants Issuance of common stock, net of transaction costs of $4.5 million Common stock issued for Merck license Conversion of convertible debt Stock-based compensation On September 12, 2007, the Board of Directors of the Company authorized a 3-for-2 split of the Company’s common stock.
2008-03-31
2007-06-19 1007.19 未披露 定期报告 2007-06-05
2007-06-19 1001.20 18.40
更多>>
from March 31, 2006 to March 31, 2007 Conversion of Series A preferred stock into common stock Exercise of stock options Private placement of equity, net of transaction costs of $63 Exercise of stock warrants Issuance of common stock for the purchase of Vilazodone rights Retirement of treasury stock Equity issued in connection with the Genome Express acquisition Stock based compensation Purchase of treasury stock
2007-03-31
2006-06-29 958.41 未披露 定期报告 2006-06-16
2006-06-29 851.00 23.40
更多>>
from March 31, 2005 to March 31, 2006 Series A preferred stock issued in connection with acquisitions Conversion of Series A preferred stock into common stock Equity issued in connection with acquisitions Exercise of stock options Private placement of equity, net of transaction costs of $83 Exercise of stock warrants Issuance of restricted stock
2006-03-31
2005-06-27 440.50 未披露 定期报告 2005-06-23
2005-06-27 439.50 未披露
更多>>
from March 31, 2004 to March 31, 2005 Exercise of stock options
2005-03-31
2004-06-28 440.71 未披露 定期报告 2004-06-23
2004-06-28 438.70 未披露
更多>>
from March 31,2003 to March 31,2004 Conversion of Series A Preferred Stock into common stock Exercise of stock options
2004-03-31
2003-06-30 188.00 未披露 定期报告 2003-06-17
2003-06-30 185.45 未披露
更多>>
from March 31,2002 to March 31,2003 Issuance of common stock in connection with the 5-for-4 stock split Exercise of stock options Purchase of treasury stock
2003-03-31
2002-07-15 148.80 未披露 定期报告 2002-07-11
2002-07-15 147.40 未披露
更多>>
from March 31,2001 to March 31,2002 Exercise of stock options Purchase of treasury stock Retirement of common stock
2002-03-31
2001-06-25 144.52 未披露 定期报告 2001-06-22
2001-06-25 143.84 未披露
更多>>
from March 31,2000 to March 31,2001 Sale of common stock Purchase of treasury stock
2001-03-31
2000-06-23 144.52 未披露
更多>>
from March 31,1999 to March 31,2000 Further issuance of common stock in connection with a 10% stock dividend of March 27, 1998 Purchase of treasury stock Sale of common stock Retirement of treasury stock
2000-03-31
1999-06-28 144.01 未披露 定期报告 1999-06-21
1999-06-28 144.89 未披露
更多>>
from March 31,1998 to March 31,1999 Further issuance of common stockin connection with a 10% stock dividend of March 27, 1998 Purchase of treasury stock
1999-03-31
1998-06-29 145.44 未披露 定期报告 1998-06-23
1998-06-29 145.42 未披露
更多>>
from March 31,1997 to March 31,1998 Issuance of common stock in connection with a 10% stock dividend
1998-03-31
1997-06-27 132.35 未披露
更多>>
On November 12,1996,the Company declared a 1 for 3 reverse stock split of the Common Stock payable on December 4,1996 to the stockholders of record on November 25,1996.
1997-03-31
1996-06-26 396.59 未披露 定期报告 1996-03-31
Equity issued in connection with the Avalon acquisition Public offering, net of transaction costs of $3,262 Exercise of stock options, net of shares surrendered Exercise of stock warrants Stock-based compensation
from March 31, 2008 to March 31, 2009 Exercise of stock options Exercise of stock warrants Issuance of common stock and warrants, net of transaction costs of $36 Retirement of treasury stock Stock-based compensation
from March 31, 2007 to March 31, 2008 Conversion of Series A preferred stock into common stock Exercise of stock options Exercise of stock warrants Issuance of common stock, net of transaction costs of $4.5 million Common stock issued for Merck license Conversion of convertible debt Stock-based compensation On September 12, 2007, the Board of Directors of the Company authorized a 3-for-2 split of the Company’s common stock.
from March 31, 2006 to March 31, 2007 Conversion of Series A preferred stock into common stock Exercise of stock options Private placement of equity, net of transaction costs of $63 Exercise of stock warrants Issuance of common stock for the purchase of Vilazodone rights Retirement of treasury stock Equity issued in connection with the Genome Express acquisition Stock based compensation Purchase of treasury stock
from March 31, 2005 to March 31, 2006 Series A preferred stock issued in connection with acquisitions Conversion of Series A preferred stock into common stock Equity issued in connection with acquisitions Exercise of stock options Private placement of equity, net of transaction costs of $83 Exercise of stock warrants Issuance of restricted stock
from March 31, 2004 to March 31, 2005 Exercise of stock options
from March 31,2003 to March 31,2004 Conversion of Series A Preferred Stock into common stock Exercise of stock options
from March 31,2002 to March 31,2003 Issuance of common stock in connection with the 5-for-4 stock split Exercise of stock options Purchase of treasury stock
from March 31,2001 to March 31,2002 Exercise of stock options Purchase of treasury stock Retirement of common stock
from March 31,2000 to March 31,2001 Sale of common stock Purchase of treasury stock
from March 31,1999 to March 31,2000 Further issuance of common stock in connection with a 10% stock dividend of March 27, 1998 Purchase of treasury stock Sale of common stock Retirement of treasury stock
from March 31,1998 to March 31,1999 Further issuance of common stockin connection with a 10% stock dividend of March 27, 1998 Purchase of treasury stock
from March 31,1997 to March 31,1998 Issuance of common stock in connection with a 10% stock dividend
On November 12,1996,the Company declared a 1 for 3 reverse stock split of the Common Stock payable on December 4,1996 to the stockholders of record on November 25,1996.
同花顺个股页面 | 模拟炒股 | 股民学校 | 手机炒股| 联系我们

免责声明:本信息由同花顺金融研究中心提供，仅供参考，同花顺金融研究中心力求但不保证数据的完全准确，如有错漏请以中国证监会指定上市公司信息披露媒体为准，同花顺金融研究中心不对因该资料全部或部分内容而引致的盈亏承担任何责任。用户个人对服务的使用承担风险。同花顺对此不作任何类型的担保。同花顺不担保服务一定能满足用户的要求，也不担保服务不会受中断，对服务的及时性，安全性，出错发生都不作担保。同花顺对在同花顺上得到的任何信息服务或交易进程不作担保。同花顺提供的包括同花顺理财的所有文章，数据，不构成任何的投资建议，用户查看或依据这些内容所进行的任何行为造成的风险和结果都自行负责，与同花顺无关。

【免责声明】本产品中的行情数据及资讯信息来源于第三方，长江证券不对收集数据的版权、真实性、准确性及传输过程中发生的传送错误承担法律责任。本内容仅供参考，不作为投资决策依据，长江证券不对因据此操作产生的盈亏承担任何责任。投资有风险，入市需谨慎。